TrialBlood advances2023

Deferiprone for transfusional iron overload in sickle cell disease and other anemias: open-label study of up to 3 years.

Mohsen S Elalfy et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.